A combination of immunotherapy and chemotherapy, with or without targeted therapy, has been approved as a first-line treatment for metastatic HER2-negative [15,16] or HER2-positive gastric adenocarcinoma [17]. Here, ERBB2 is linked to gastric adenocarcinoma.